Viking Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
(a)(1) The Financial Statements required to be filed by Items 8 and 15(c) of this Annual Report on Form 10-K, and filed herewith, are as follows:
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm | F-4 |
| Consolidated Balance Sheets | F-5 |
| Consolidated Statements of Operations and Comprehensive Loss | F-6 |
| Consolidated Statements of Stockholders’ Equity | F-7 |
| Consolidated Statements of Cash Flows | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
(a)(2) Financial Statement Schedules have been omitted because they are either not applicable or the required information is included in the financial statements or notes thereto listed in (a)(1) above.
(a)(3) Exhibits.
The following exhibits are filed herewith or incorporated herein by reference:
| ExhibitNumber | Description | Registrant’sForm | Date Filedwith theSEC | ExhibitNumber |
|---|---|---|---|---|
| 3.1 | Amended and Restated Certificate of Incorporation. | S-1 | 7/1/2014 | 3.3 |
| 3.2 | Amended and Restated Bylaws of Viking Therapeutics, Inc., effective as of May 9, 2023. | 8-K | 5/11/2023 | 3.1 |
| 4.1 | Form of Common Stock Certificate. | S-1 | 7/1/2014 | 4.1 |
| 4.2 | Description of Registrant’s Securities. | 10-K | 2/1/2023 | 4.2 |
| 10.1# | Form of Indemnification Agreement between Viking Therapeutics, Inc. and its directors and executive officers. | S-1 | 7/1/2014 | 10.1 |
| 10.2# | 2014 Equity Incentive Plan. | S-1/A | 3/2/2015 | 10.2 |
| 10.3# | 2024 Equity Incentive Plan. | S-8 | 5/22/2024 | 4.2 |
| 10.4# | Form of Stock Option Award Agreement (2024 Equity Incentive Plan). | S-8 | 5/22/2024 | 4.3 |
| 10.5# | Form of Restricted Stock Unit Award Agreement (2024 Equity Incentive Plan). | S-8 | 5/22/2024 | 4.4 |
| 10.6# | Form of Restricted Stock Award Agreement (2024 Equity Incentive Plan). | S-8 | 5/22/2024 | 4.5 |
| 10.7# | 2024 Employee Stock Purchase Plan. | S-8 | 5/22/2024 | 4.6 |
| 10.8# | Employment Agreement, effective as of June 2, 2014, by and between Viking Therapeutics, Inc. and Brian Lian, Ph.D. | S-1/A | 9/2/2014 | 10.6 |
| 10.9# | First Amendment to Employment Agreement, effective as of March 14, 2016, by and between Viking Therapeutics, Inc. and Brian Lian, Ph.D. | 8-K | 3/15/2016 | 10.1 |
| 10.10# | Employment Agreement, effective as of May 21, 2025, by and between Viking Therapeutics, Inc. and Marianne Mancini. | 10-K | 2/26/2025 | 10.10 |
| ExhibitNumber | Description | Registrant’sForm | Date Filedwith theSEC | ExhibitNumber |
|---|---|---|---|---|
| 10.11# | Employment Agreement, effective as of May 21, 2025, by and between Viking Therapeutics, Inc. and Greg Zante. | 10-K | 2/26/2025 | 10.11 |
| 10.12#* | Non-Employee Director Compensation Policy. | |||
| 10.13† | Master License Agreement, dated May 21, 2014, by and among Viking Therapeutics, Inc., Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc. | 10-Q | 7/24/2024 | 10.1 |
| 10.14† | First Amendment to Master License Agreement, dated September 6, 2014, by and among Viking Therapeutics, Inc., Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc. | 10-Q | 7/24/2024 | 10.2 |
| 10.15† | Second Amendment to Master License Agreement, dated April 8, 2015, by and among Viking Therapeutics, Inc., Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc. | 10-Q | 7/24/2024 | 10.3 |
| 10.16#† | Common Stock Purchase Agreement, dated February 20, 2014, by and between Viking Therapeutics, Inc. and Brian Lian, Ph.D. | 10-K | 2/26/2025 | 10.11 |
| 10.17# | Amendment No. 1 to Common Stock Purchase Agreement, dated May 4, 2015, by and between Viking Therapeutics, Inc. and Brian Lian, Ph.D. | 10-Q | 6/12/2015 | 10.5 |
| 10.18#*† | Amendment No. 2 to Common Stock Purchase Agreement, dated May 17, 2025, by and between Viking Therapeutics, Inc. and Brian Lian, Ph.D. | |||
| 10.19#*† | Amendment No. 3 to Common Stock Purchase Agreement, dated October 27, 2025, by and between Viking Therapeutics, Inc. and Brian Lian, Ph.D. | |||
| 10.20† | Strategic Manufacturing and Supply Agreement, dated March 10, 2025, by and among Viking Therapeutics Ireland Limited, Corden Pharma Schweizerhalle GmbH, Corden Pharma GmbH and Corden Pharma Colorado, Inc. | 10-Q | 4/24/2025 | 10.1 |
| 10.21† | Prepayment Agreement, dated March 10, 2025, by and among Viking Therapeutics Ireland Limited, Corden Pharma Schweizerhalle GmbH, Corden Pharma GmbH and Corden Pharma Colorado, Inc. | 10-Q | 4/24/2025 | 10.2 |
| 10.22† | Manufacturing and Supply (Drug Product) Agreement, dated March 10, 2025, by and among Viking Therapeutics Ireland Limited, Corden Pharma GmbH, Corden Pharma Lisbon S.A. and Corden Pharma S.p.A. | 10-Q | 4/24/2025 | 10.3 |
| 10.23 | At-The-Market Equity Offering Sales Agreement, dated as of July 28, 2021, by and among Viking Therapeutics, Inc., Stifel, Nicolaus & Company, Incorporated Truist Securities, Inc. and H.C. Wainwright & Co., LLC. | S-3 | 7/28/2021 | 1.2 |
| 10.24 | Amendment No. 1 to At-the-Market Equity Offering Sales Agreement, dated as of July 26, 2023, by and among Viking Therapeutics, Inc., Stifel, Nicolaus & Company, Incorporated, Truist Securities, Inc., H.C. Wainwright & Co., LLC and BTIG, LLC. | 10-Q | 7/26/2023 | 10.1 |
| 19 | Insider Trading Policy | 10-K | 2/26/2025 | 19 |
| 21.1 | List of Subsidiaries of Viking Therapeutics, Inc. | 10-K | 2/26/2025 | 21.1 |
| 23.1* | Consent of CBIZ CPAs P.C., Independent Registered Public Accounting Firm. | |||
| ExhibitNumber | Description | Registrant’sForm | Date Filedwith theSEC | ExhibitNumber |
|---|---|---|---|---|
| 23.2* · Consent of Marcum LLP, Independent Registered Public Accounting Firm. | ||||
| 31.1* · Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. | ||||
| 31.2* · Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. | ||||
| 32.1* · Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 97 | Viking Therapeutics, Inc. Clawback Policy | 10-K | 2/7/2024 | 97 |
| 101.INS | Inline XBRL Instance Document–the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | |||
| 104 | Cover page formatted as Inline XBRL and contained in Exhibit 101 | |||
Attached as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2025 and December 31, 2024, (ii) Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025, 2024 and 2023, (iii) Consolidated Statements of Stockholders’ Equity for the period from December 31, 2023 to December 31, 2025, (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023, and (v) Notes to Consolidated Financial Statements.
- Filed herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.